Page 8 - ABUS-Casestudy

Learn more about
Invenia ABUS

About GE HealthCare
GE HealthCare is a leading global medical technology,
pharmaceutical diagnostics, and digital solutions innovator,
dedicated to providing integrated solutions, services, and data
analytics to make hospitals more efficient, clinicians more effective,
therapies more precise, and patients healthier and happier. Serving
patients and providers for more than 100 years, GE HealthCare is
advancing personalized, connected, and compassionate care, while
simplifying the patient’s journey across the care pathway. Together
our Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical
Diagnostics businesses help improve patient care from prevention
and screening, to diagnosis, treatment, therapy, and monitoring.
We are an $18 billion business with 51,000 employees working to
create a world where healthcare has no limits.

Follow us on Facebook, LinkedIn, Twitter, Instagram and Insights
for the latest news, or visit our website gehealthcare.com for
more information.

References:
1. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2020). Global
Cancer Observatory: Cancer Today. Lyon, France: International Agency for International Agency for Research
on Cancer. Latest global cancer data: Cancer burden rises to 19.3 million new cases and 10.0 million cancer
deaths in 2020. Press release 292. 15 December 2020.
2. Sardanelli, F., Aase, H.S., Álvarez, M. et al., Position paper on screening for breast cancer by the European
Society of Breast Imaging (EUSOBI) and 30 national breast radiology bodies from Austria, Belgium, Bosnia
and Herzegovina, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece,
Hungary, Iceland, Ireland, Italy, Israel, Lithuania, Moldova, The Netherlands, Norway, Poland, Portugal,
Romania, Serbia, Slovakia, Spain, Sweden, Switzerland and Turkey, Eur Radiol (2016). doi:10.1007/
s00330-016-4612-z.
3. Boyd, et al: Mammographic density and the risk and detection of breast cancer, NEJM Jan 2007

4. Wilczek Brigitte, Wilczek Henryk E, Rasouliyan Lawrence, Leifland Karin, Adding 3D Automated Breast
Ultrasound to mammography screening in women with heterogeneously and extremely dense breasts.
Report from a hospitalbased, high-volume, single-center breast cancer screening program., European
Journal of Radiology http://dx.doi.org/10.1016/j.ejrad.2016.06.004.
5. A. Vourtsis et.al, The performance of 3D ABUS versus HHUS in the visualisation and BI-RADS
characterisation of breast lesions in a large cohort of 1,886 women. Eur Radiol. 2018 Feb;28(2):592-601.
doi: 10.1007/s00330-017-5011-9.
6. Mann, R.M., Athanasiou, A., Baltzer, P.A.T. et al. Breast cancer screening in women with extremely dense
breasts recommendations of the European Society of Breast Imaging (EUSOBI). Eur Radiol 32, 4036–4045
(2022). https://doi.org/10.1007/s00330-022-08617-6.
7. The effectiveness of Automated Breast Ultrasound as a personalized screening tool in women with dense
breasts. GE Breast Magazine Article Dr. Vourtsis, JB25060XX.
8. https://www.who.int/news-room/fact-sheets/detail/breast-cancer.

Products mentioned in the material may be subject to government regulations and may not be available in
all countries. Shipment and effective sale can only occur after approval from the regulator. Please check with
local GE HealthCare representative for details.
©2023 GE HealthCare. Invenia is a trademark of GE HealthCare. GE is a trademark of General Electric
Company used under trademark license. BI-RADS is a trademark of American College of Radiology.
June 2023
JB25090XX